

09/359 920



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 45/06	A1	(11) International Publication Number: WO 00/10609
		(43) International Publication Date: 2 March 2000 (02.03.00)
(21) International Application Number: PCT/US99/19480 (22) International Filing Date: 25 August 1999 (25.08.99) (30) Priority Data: 09/139,425 25 August 1998 (25.08.98) US (71) Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION [US/US]; 825 N.E. Thirteenth Street, Oklahoma City, OK 73104 (US). (72) Inventors: ESMON, Charles, T.; 5800 North Stonewall, Oklahoma City, OK 73111 (US). XU, Jun; 3630 North Villa, No. 4, Oklahoma City, OK 73112 (US). (74) Agents: PABST, Patrea, L. et al.; Arnall Golden & Gregory, LLP, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: TARGETING OF MOLECULES TO LARGE VESSEL ENDOTHELIUM USING EPCR		
(57) Abstract Endothelial protein C receptor (EPCR) is found primarily on endothelial cells of large vessels. EPCR translocates from the plasma membrane surface to the nucleus. Molecules which bind to EPCR can be carried from the plasma membrane surface to the nucleus. These molecules include antibodies to EPCR and activated protein C. Protein C, which also binds to EPCR, can be internalized by endothelial cells, but does not enter the nucleus. Thus, EPCR translocation from the plasma membrane to the nucleus provides a means of delivering nucleic acid such as DNA, proteins such as transcription factors, diagnostic agents or other types of drugs to the nucleus of endothelial cells, particularly those on large blood vessels. Conjugates of the materials to be delivered to the nucleus can be formed by ionic or covalent coupling. For example, proteins, including fusion proteins, can be directly conjugated to an anti-EPCR monoclonal antibody. Covalent attachment of positively charged polymers, such as polylysine, to an anti-EPCR antibody allows nucleic acid to bind by ionic charges. Streptavidin and biotin can also be used to conjugate molecules to anti-EPCR antibodies. These conjugated antibodies are transported to the nucleus by EPCR. Examples demonstrate selective transport to the nucleus which is mediated by EPCR. Molecules transported include activated protein C, antibodies to EPCR, and streptavidin-biotin conjugates. Modification of anti-EPCR monoclonal antibodies by covalently coupling to polylysine allows binding of an expression vector to the modified antibody and translocation to the nucleus.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TARGETING OF MOLECULES TO LARGE VESSEL ENDOTHELIUM USING EPCR

The United States government has certain rights in this invention by
virtue of National Heart, Lung and Blood Institute of the Institutes of Health
grant No. P01 HL54804 to Charles T. Esmon.

Background of the Invention

The present invention is generally in the area of targeting delivery of
nucleotides and other molecules to large vessel endothelium using the
endothelial cell protein C/activated protein C receptor ("EPCR").

Endothelial cells are a primary defense mechanism against cellular
infiltration and thrombosis. Abnormal function of the endothelial cells
contributes to myocardial infarction (MI), stroke and the development of
atherosclerotic plaque. Atherosclerosis and most other vascular disease
primarily occur in large vessels. In particular, large vessels are prone to a
variety of diseases leading to atherosclerosis and thrombosis, resulting in
heart attacks, strokes, deep vein thrombosis and pulmonary emboli. Gene
therapy to modify the vascular lesions would be desirable.

Unfortunately, targeting endothelial cells non-specifically is often
inadequate. Since more than 95% of endothelial cells are in the capillaries,
arterioles and postcapillary venules, any therapy directed toward endothelial
cells *per se* runs the risk of systemic complications. One must be confident
that the gene expression is limited to the desired cells when using a gene
therapy approach. However, no means for specifically targeting delivery to
large vessel endothelium, in contrast to small vessel endothelium, or other
types of tissues, are known.

It is therefore an object of the present invention to provide a means
for specifically targeting delivery to large vessel endothelium.

It is a further object of the present invention to provide a means for
delivering an agent to the endothelial cell nucleus of large vessels.

Summary of the Invention

EPCR is located primarily on the surface of endothelial cells of large
vessels. It translocates from the cell surface to the nucleus, and can be used
to direct uptake by the cells of molecules that bind to EPCR and materials

covalently coupled to the EPCR binding molecules. Molecules which bind to the EPCR, such as activated protein C ("APC"), but not protein C ("PC"), will be transported specifically to the nucleus of endothelial cells, especially those of the large vessels. Molecules which bind to the EPCR, such as PC, will direct molecules to endothelial cells, especially those of the large vessels. Molecules to be delivered can be nucleic acid, such as DNA, proteins such as transcription factors, diagnostic agents or other types of drugs. Conjugates of the materials to be administered can be formed by ionic or covalent coupling, for example, through direct conjugation of an anti-EPCR monoclonal antibody to a protein, including fusion proteins, or through the covalent attachment of a positively charged polymer such as polylysine to an anti-EPCR antibody, where the positively charged polymer binds nucleic acid or other negatively charged molecules by ionic charges. Streptavidin and biotin can also be used to conjugate molecules to the anti-EPCR antibody.

Examples demonstrate selective transport to the nucleus mediated by antibodies to EPCR, transport of proteins and genes bound to the antibodies to EPCR by charged polymers and streptavidin-biotin coupling, and transport selectively of APC, but not PC, to the nucleus of large vessel endothelial cells.

Brief Description of the Drawings

Figure 1 is a graph of reporter gene transfer via a DNA anti-EPCR mAb-poly-L-lysine complex. Luciferase gene expression was measured in EA.hy926 cells transfected with the DNA-mAb conjugate as described in the experimental procedures. Control is the EA.hy926 cells transfected with same amounts of DNA, mAb and poly-L-lysine.

Figure 2 is a graph of ^{125}I streptavidin nuclear delivery via biotinylated anti-EPCR mAb EA.hy926 cells cultured with 13.9 nM ^{125}I labeled streptavidin in the absence (-) or presence (+) of 11.1 nM biotinylated anti-EPCR mAb(JRK1500) for 1 hr at 37° C.

Figure 3 is a graph of EPCR mediated nuclear translocation of APC, but not protein C, in human umbilical vascular endothelial cells ("HUVEC").

Detailed Description of the Invention

I. Delivery System Targeted to Large Vessel Endothelium

A. EPCR

The endothelial cell protein C receptor is ideally suited to target
5 genes or other materials to the endothelial cell population of choice. The protein is expressed at the highest levels on endothelium of large vessels, particularly arteries and is at very low or undetectable levels in capillaries, as described by Laszik, et al., *Circulation* 96, 3633-3640 (1997) and PCT/US97/20364 "Endothelium Specific Expression Regulated by EPCR
10 Control Elements" Oklahoma Medical Research Foundation. Protein C can be seen to be associated with vessels that express EPCR, but not with those that do not.

EPCR was cloned and characterized, as described in PCT/US95/09636 "*Cloning and Regulation of an Endothelial Cell Protein
15 C/Activated Protein C Receptor*" by the Oklahoma Medical Research Foundation and U.S. Patent No. 5,695,993 issued December 9, 1997, to Oklahoma Medical Research Foundation. The protein consists of 238 amino acids, which includes a 15 amino acid signal sequence at the N-terminus, and a 23 amino acid transmembrane region which characterizes the receptor as a
20 type 1 transmembrane protein. The protein binds with high affinity to both protein C and activated protein C ($K_d=30$ nM), which is a naturally occurring anticoagulant, and binding is calcium dependent. A vector encoding EPCR can be obtained from Invitrogen Corporation, 3985B Sorrento Valley Boulevard, San Diego, California 92121.

25 The method used herein is preferably used with cells that naturally express EPCR, although it is understood that cells that are genetically engineered to express EPCR can also be targeted using agents which bind EPCR, to obtain uptake by the EPCR-expressing cells of material conjugated to the EPCR-binding molecules.

30 B. Agents which bind to EPCR

Agents which selectively bind to EPCR can be used to deliver materials selectively to large vessel endothelial cells. Exemplary agents include PC, antibodies and antibody fragments which bind to EPCR, and

certain other proteins, including fusion proteins, which include the Gla domain of PC. Selection of the agent can be used to target the molecule to be delivered to either the nucleus or to the cytoplasm of the large vessel endothelial cells. For example, APC directs uptake to the nucleus; PC results in uptake primarily within the cytoplasm and organelles therein.

Antibodies to EPCR, whether they block protein C binding or not, are transported to the nucleus. This is because EPCR translocates to the nucleus, not because of antibody dependent translocation. As described in the examples, polyacrylamide gel electrophoresis in detergent ("SDS-PAGE") and autoradiography shows ¹²⁵I labeled monoclonal antibody ("Mab") deposition in the nucleus as detected in nuclear extracts of the HUVEC. Mab 1500 does not block protein C binding to EPCR whereas Mab 1494 does block this binding. Antibodies are found in the nuclear extract. Control antibodies to Thrombomodulin are not detected in the nuclear extract.

Antibodies which can be used to bind to EPCR include polyclonal and monoclonal antibodies, and fragments thereof, produced by enzymatic cleavage or expression of recombinant nucleic acid molecules encoding the fragments. Methods for making EPCR and antibodies to EPCR are described by Stearns-Kurosawa, et al., *J. Biol. Chem.* 271, 17499-17503 (1996). Antibodies can be obtained using standard techniques using EPCR, either isolated from natural or recombinant sources as the immunogen. The antibodies can be used as naturally produced, cleaved enzymatically to yield fragments, or expressed from recombinant genes. Monoclonal antibodies can also be generated using standard techniques.

Recombinant and humanized antibodies can also be made using standard techniques. For example, Pharmacia's (Pharmacia LKB Biotechnology, Sweden) "Recombinant Phage Antibody System" (RPAS), which generates a single-chain Fv fragment (ScFv) that incorporates the complete antigen-binding domain of the antibody can be used to make antibodies. In the RPAS, antibody variable heavy and light chain genes are separately amplified from the hybridoma mRNA and cloned into an expression vector. The heavy and light chain domains are co-expressed on the same polypeptide chain after joining with a short linker DNA which

codes for a flexible peptide. This assembly generates a single-chain Fv fragment (ScFv) which incorporates the complete antigen-binding domain of the antibody. Murine ScFv molecules can be "humanized" to further reduce the immunogenic stimulus presented.

5 Methods for "humanizing" antibodies, or generating less immunogenic fragments of non-human antibodies, are well known. A humanized antibody is one in which only the antigen-recognized sites, or complementarity determining hypervariable regions (CDRs) are of non-human origin, whereas all framework regions (FR) of variable domains are
10 products of human genes. These "humanized" antibodies present a lesser xenograft rejection stimulus when introduced to a human recipient. To accomplish humanization of a selected mouse monoclonal antibody, the CDR grafting method described by Daugherty, et al., *Nucl. Acids Res.*, 19:2471-2476, 1991, can be used. Briefly, the variable region DNA of a
15 selected animal recombinant anti-idiotypic ScFv is sequenced by the method of Clackson, T., et al., *Nature*, 352:624-688, 1991. Using this sequence, animal CDRs are distinguished from animal framework regions (FR) based on locations of the CDRs in known sequences of animal variable genes. Kabat, H.A., et al., *Sequences of Proteins of Immunological Interest*, 4th Ed.
20 (U.S. Dept. health and Human Services, Bethesda, MD, 1987). Once the animal CDRs and FR are identified, the CDRs are grafted onto human heavy chain variable region framework by the use of synthetic oligonucleotides and polymerase chain reaction (PCR) recombination. Codons for the animal heavy chain CRDs, as well as the available human heavy chain variable
25 region framework, are built in four (each 100 bases long) oligonucleotides. Using PCR, a grafted DNA sequence of 400 bases is formed that encodes for the recombinant animal CDR/human heavy chain FR protection.

Other molecules which can be used include proteins such as activated protein C ("APC"), or other proteins which include the vitamin K specific
30 Gla domain of protein C, to direct binding to EPCR. Activated protein C is targeted to the nucleus and hence can be used to carry other proteins or DNA into the nucleus. In contrast, protein C is internalized by the receptor, but the protein C is not targeted to the nucleus. Nevertheless, protein C could be

modified with an expression vector and could serve as a means of delivering genes to large vessel endothelium. The genes could then be targeted to the nucleus by a variety of means including attachment of nuclear targeting amino acid peptide sequences to the DNA such as the SV40 nuclear targeting sequence, described by Sebestyén, et al., *Nature Biotechnology* 16, 80-85 (1998).

C. Molecules to be Delivered

A variety of materials can be delivered, ranging from nucleic acids to proteins to diagnostic agents to drugs. In the preferred embodiment, these materials will be directed to the nucleus, particularly in the case of molecules to be expressed.

Nucleic acid molecules include vectors for expression of a gene or cDNA encoding a particular protein, molecules which inhibit or alter expression of a particular endogenous nucleic acid molecule, such as an antisense molecule, triplex forming oligonucleotide, ribozyme or external guide sequence for a ribozyme.

Many different genes have been identified as candidates to minimize vascular defects including tissue plasminogen activator, agents to inhibit the expression of leukocyte adhesion molecules, thrombomodulin, nitric oxide synthase, etc. The delivery of proteins or protein expression inhibitors, directly or via gene therapy, specifically to large vessel endothelial cells, is one means for addressing these clinical conditions. For example, the anti-thrombotic potential of endothelium can be increased by delivering agents that prevent thrombosis, such as thrombomodulin, heparin proteoglycans, tissue factor pathway inhibitor (TFPI, a potent inhibitor of the tissue Factor-Factor VIIa-Factor X complex), etc. Fibrinolytic activity can be increased by overexpression of tissue plasminogen activator (tPA) or urokinase. Expression of adhesion molecules such as P-selectin or ICAMs can be inhibited to minimize or decrease leukocyte infiltration. Transcription factors can be used to induce expression of particular proteins.

Diagnostic agents include molecules which can be used for diagnostic

purposes, including radiolabels, fluorescent labels, enzymatic labels, and other materials.

Drugs include molecules which are not normally transported efficiently, or selectively, into endothelial cells, especially those of the large vessels. These may be antiinflammatories, anticoagulants, anti-cytokines, growth hormones, or of any other purpose for which transport into endothelial cells is desirable.

Immunoprecipitates of surface biotinylated EPCR shown as a function of time demonstrate that, since both the surface labeled EPCR and the antibody EPCR complex translocate to the nucleus, translocation is independent of the antibody and hence any agent that binds tightly to EPCR can be translocated to the nucleus. For instance, a luciferase reporter gene construct bound to polylysine modified anti-EPCR monoclonal antibodies can be transported to the nucleus as evidenced by the antibody dependent expression of luciferase, as shown by the examples. No expression occurs if the construct is added to antibody that has not been modified with polylysine.

D. Methods of Binding to EPCR

The molecules to be delivered must be coupled to the agents which bind to the EPCR. The molecules can be conjugated directly or indirectly to the agents which bind to the EPCR. Binding can be covalent or ionic. Direct binding can be obtained using standard chemical coupling techniques such as using succinic anhydride and published methodology or by expression of the agent and molecule as a fusion protein. Indirect binding can be obtained through an intermediate molecule, such as a positively charged polymer like lysine (which binds to negatively charged molecules such as DNA), streptavidin which binds to biotin, either of which can be conjugated to the agent binding the EPCR, or expressed as a fusion protein with the agent binding the EPCR, or through the use of a chimeric antibody which binds both the EPCR and the molecules to be delivered.

Examples of useful chimeric antibodies include antibodies which bind both EPCR and DNA and antibodies which bind to both EPCR and whatever other molecule is to be delivered. Chimeric antibodies can be

made using standard techniques. For example, chimeric antibodies composed of one variable region of anti-DNA antibody can be fused to one variable region of anti-EPCR antibody. Preferably both antibodies are humanized to minimize the immune response.

5 An example of protein delivery to the nucleus of large vessel endothelial cells is shown in the examples. Streptavidin was carried into the nucleus on biotinylated anti-EPCR mAB, JRK 1500.

 Agents binding to EPCR can be coupled to molecules such as polylysine, polypyrroles, chitosan and other molecules known to ionically
10 bind to DNA or other negatively charged molecules to be delivered. These are typically polymers including numerous positively charged groups.

II. Methods for Administration

 Translocation of cell surface receptors to the nucleus has previously been shown for other receptors, including the receptors for fibroblast growth
15 factor (FGF) (Maher, P.A. *J. Cell Biol.* 134:529-536 (1996)), epidermal growth factor (EGF) (Holt, et al., *Biochem. Pharmacol.* 47:117- 126 (1994; Xie, Y. and M.-C. Hung. *Biochem. Biophys. Res. Comm.* 203:1589-1598 (1994)); insulin (Jiang, L.-W. and M. Schindler. *J. Cell Biol.* 110:559-568 (1990)), interleukin 1 (Curtis, et al. *J. Immunol.* 144:1295-1303 (1990)),
20 growth hormone (Lobie, et al. *J. Biol. Chem.* 269:31735-31746 (1994)). In all of these cases, translocation requires binding of the receptor ligand to the receptor. Many of these ligands have adverse biological effects causing cellular proliferation (FGF and EGF) or inflammation (IL-1) (Curtis, et al. 1990) and hence the agonist is inappropriate for general therapy.

25 As described herein, a delivery means has been developed which is restricted to large vessel endothelium and hence can serve to deliver genes, transcription factors or other cellular modifiers to the nucleus of the large vessel endothelium specifically where the major complications of many cardiovascular diseases are manifested primarily. In the case of EPCR
30 nuclear translocation, serum stimulates the process, but is not required. This means that enhanced delivery may be obtained during inflammation or coagulation processes, which typically accompany the disorders to be

treated, or are more pronounced in the areas of the patient where treatment is desired.

In the preferred embodiment, the conjugate of the agent binding to the EPCR and the molecule to be delivered is administered intravascularly to a patient for administration throughout the blood vessels of the body. In another embodiment, the conjugate is administered to a region of a body in need of treatment thereof, for example, during angioplasty. Alternatively, the material can be used *in vitro*, to treat isolated cells, which can remain in culture or be returned to a patient in need of treatment thereof. The number of molecules to be administered will be determined empirically, based on the efficiency of uptake, the condition to be treated, the number of cells to be treated, the severity of the condition, and other variables normally considered in determining an effective amount.

The conjugate will typically be administered in an appropriate pharmaceutically acceptable carrier such as phosphate buffered saline, saline, or other materials used for administration of drugs intravenously. Conjugate can be administered alone or in combination with other therapeutic agents, such as anticoagulants, antiinflammatories, vasoconstrictors or other drugs appropriate for treatment of the disease indication.

The conjugate can alternatively be administered in a carrier such as a polymeric gel if applied topically or locally, for example, during angioplasty, particularly if administered using the angioplastic catheter, or directly, during surgery. Such catheters and polymeric materials are known, for example, as described in U.S. Patent Nos. 5,779,673 to Roth, et al., 5,749,968 to Melanson, et al., and 5,698,189 to Rowe, et al. See also WO 96/20732 by Chiron Viagene which discloses polymeric materials such as polybrene to enhance transfer of material into cells to be genetically engineered and WO 96/21470 by Genemedicine, Inc. which describes polymers such as the polyoxyethylene oxides (PluronicTM and PolaxomersTM sold by BASF) to retain genetic material at a site for transduction, and to increase efficiency of transduction. Other carriers can also be used, such as microparticles which provide for controlled release.

The amount to be administered can be determined based on the in vivo half-life of the conjugate, the efficiency of uptake, and the area to be treated. Treatment can be repeated as necessary, based on clinical judgement, in view of patient response. A pharmaceutically effective amount is that which achieves a clinical response, depending on the disorder to be treated.

The present invention will be further understood by reference to the following non-limiting examples.

Experimental Procedures

10 *Isolation of Nuclei and Nuclear Extracts*

Cells in 100 mm culture dishes were rinsed three times with cold Hank's buffered salt solution, (HBSS), and suspended in 1.5 ml of cold cell lysis buffer (10 mM HEPES, pH7.5, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF) by gentle scraping with a rubber policeman. The cells were allowed to swell on ice for 15 min, then 93.8 µl of a 10% solution of NP-40 was added and the tube was vortexed vigorously for 10 sec. Nuclei were pelleted by centrifugation for 30 sec in a microfuge, and washed twice with cell lysis buffer containing 0.5% NP-40. The nuclear pellets were extracted by nuclear extraction buffer (0.1% NP-40, 20 mM HEPES, pH 7.5, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aproptinin, 1 mM benzamidine) at 4 °C for 1 hr. Nuclear extracts were present in the supernatants after centrifugation at 4 °C for 15 min.

Translocation of EPCR from the plasma membrane to the nucleus

25 Cells in 100 mm culture dishes were labeled for 10 min at RT with 0.5 mg/ml sulfo-NHS-LC- Biotin in HBSS with 1 mM Mg²⁺ and Ca²⁺, rinsed with HBSS 1 M Ca²⁺ and Mg²⁺, and then cultured with fresh medium at 37 °C for the indicated time. The cells were rinsed with ice-cold HBSS, lysed and the nuclear extracts were prepared as described above. The cell lysates without nuclei and nuclear extracts were immunoprecipitated with an anti-EPCR mAb (JRK1496, a murine anti- human EPCR antibody which blocks PC/APC binding to EPCR) resin at 4 °C for 2 hr, and the immunoprecipitates were washed with 2 M NaCl, 20 mM Tris-HCl, pH 7.5

with 0.1% LubrolTM PX twice and 0.15 M NaCl, 20 mM Tris-HCl, pH 7.5 with 0.1% LubrolTM PX twice, eluted by boiling for 3 min in 50% ethylene glycol, 5 mM MES, pH6.0, 0.1% LubrolTM PX plus 1X Laemmli sample buffer. Samples were subjected to 10% SDS-PAGE. Western blots were
5 performed using streptavidin conjugated horse radish peroxidase (HRP) and developed with ECL system (Amersham).

Immunofluorescence Microscopy

HUVECs were rinsed with HBSS (1 mM Ca²⁺, Mg²⁺), fixed for 5 min with 4% paraformaldehyde in HBSS, and permeabilized for 5 min with
10 0.05% saponin. Permeabilized cells were incubated with 1% BSA for 30min and then incubated with a mAb anti-EPCR (JRK1501, a murine monoclonal antibody to human EPCR which blocks PC/APC binding to EPCR, 10 g/ml) and a rabbit pAb anti-caveolin (10 µg/ml) in HBSS for 30 min, rinsed with HBSS, stained with FITC-conjugated goat anti-rabbit IgG (10 µg/ml) and
15 Cy3 conjugated goat anti-mouse IgG (10 µg/ml) in HBSS for 30 min, rinsed with HBSS. Slides were mounted with Slow Fade and sealed with nail polish. Dual labeled cells were examined with a laser scanning confocal microscope. (The Cy3 conjugated goat anti mouse IgG stained the nucleus and caucolae providing confirmation of nuclear localization.)

DNA-mAb complex and transfection

1.7 mg mAb anti-EPCR (JRK1500, an antibody that does not block protein C binding) in 1 ml 10 mM sodium phosphate buffer, pH 7.0 was mixed with 0.25 ml 0.1 M sodium periodate in the same buffer, incubated for 15 min at room temperature (RT). The reaction mixture was buffer
25 exchanged with 1 mM sodium acetate buffer, pH 4.0 on a PD-10 column(Pharmacia), 1.5 ml periodate oxidized mAb (1.4 mg) was collected and mixed with 0.5 ml poly-L-lysine (3 mg, mol. wt.= 20,000) in 20 mM sodium carbonate buffer, pH 9.5, and incubated for 2 hr at RT. Sodium borohydride (0.1 ml, 4 mg/ml) was added and the reaction mixture then
30 incubated on ice water for 1 hr. Free poly-L-lysine was removed by four cycles of concentration and 10 fold dilution with 10 mM glycine, pH 4.2 using a Millipore BIOMAX-100KTM ultrafilter. The overall yield of mAb-poly-L-lysine conjugate was about 70%.

The DNA-mAb complex was made by mixing 0.625 μ g pGL3 vector which contains the luciferase insert (Promega) in 50 μ l 10 mM HEPES, pH 7.5, 150 mM NaCl (HBS) and 0.42 OD₂₈₀ mAb-poly-L-lysine conjugate in 50 μ l HBS and incubating for 30 min at RT. EA.hy296 cells were cultured in 12 well plates in 50 μ l 10 mM HEPES, pH 7.5, 150 mM NaCl (HBS) with 0.42 OD₂₈₀ mAb-poly-L-lysine conjugate in 50 μ l HBS and incubating for 30 min at RT. EA.hy926 cells were cultured in 12 well plates in Dulbecco's minimal essential medium containing 10% supplemented calf serum to 70% confluency. The media was replaced with 0.9 ml fresh media and 100 μ l of the DNA-mAb complex was then added.

Example 1: Transport of Iodinated EPCR mAb into the nucleus of endothelial cells.

Human umbilical vein endothelial cells (HUVEC) were cultured with 30 nM ¹²⁵I labeled Fab of anti-EPCR mAb (JRK 1500) for 1 hr at 37°C. Approximately 10% of the cell associated anti-EPCR mAb was found in the nuclear extract (4,496 of the 43,944 cpm bound).

Example 2: Transport of biotinylated EPCR mAb into the nucleus over time.

EPCR nuclear translocation was visualized, at 0, 0.5, 1, 2 and 3 hours. EA.hy926 cells were surface biotinylated and then cultured for the indicated time at 37° C. Cell lysates (excluding the nucleus) and nuclear extracts were immunoprecipitated by an anti-EPCR mAb resin. The immunoprecipitates were subjected to SDS-PAGE under reducing conditions and Western Blotting.

The results show that biotin-labelled EPCR was present in both the nuclear extracts as well as the cell lysates, excluding the nucleus. Maximum nuclear uptake occurred within 2 hrs.

Example 3: Transfer of DNA complexed with poly-L-lysine conjugated with anti-EPCR mAb.

Figure 1 is a graph of reporter gene transfer via a DNA anti-EPCR mAb-poly-L-lysine complex. Luciferase gene expression was measured in EA.hy926 cells transfected with the DNA-mAb conjugate as described in the

experimental procedures. Control is the EA.hy926 transfected cells transfected with the same amounts of DNA, mAb and Poly-L-lysine but without polylysine conjugation.

5 The results demonstrate that there is much higher reporter gene transfer in the transfected cells, establishing that DNA can be transported into cell nuclei using a mAb to EPCR.

Example 4: Biotin labeled EPCR mAb can be used for nuclear delivery of streptavidin conjugated moieties.

10 Figure 2 is a graph of ^{125}I streptavidin nuclear delivery via biotinylated anti-EPCR mAb. EA.hy926 cells cultured with 13.9 nM ^{125}I labeled streptavidin in the absence (-) or presence (+) of 11.1 nM biotinylated anti-EPCR mAb(JRK1500) for 1 hr at 37° C.

The results demonstrate that the streptavidin can be delivered to the nucleus.

15 **Example 5: APC, but not protein C, is transported to the nucleus of endothelial cells by EPCR.**

Figure 3 is a graph of EPCR mediated nuclear translocation of APC, but not protein C, in HUVEC. HUVEC were incubated for 10 min at room temperature with or without 200 nM anti-EPCR mAb JRK 1494, an antibody that blocks protein C and binding and activity. The cells were then 20 incubated with 30 nM ^{125}I labeled APC or protein C for 1 hr at 37°C. Cells were washed with HBSS containing 0.5 mM EDTA to remove surface associated APC/protein C before the nuclei were isolated. The amounts of nuclear APC and protein C were calculated based on the specific activity of 25 the labeled proteins.

In the case of APC, approximately 8% of the cell associated counts were in the nucleus. Negligible counts were associated with the nucleus when protein C was used.

Example 6: Stimulation by Serum of EPCR Translocation.

30 Serum stimulates EPCR nuclear translocation. EA.hy926 cells were surface biotinylated and then cultured in the absence or presence of bovine serum for 1 hr at 37° C. Cell lysate (excluding nucleus) and nuclear extracts were immunoprecipitated by an anti-EPCR mAb resin. The

immunoprecipitates were subjected to SDA-PAGE under reducing conditions and Western Blotting.

The results show that a large portion of the biotin-labelled EPCR is transported into the nucleus. This means that clotting in an area could in
5 some cases increase therapeutic gene/agent uptake.

We claim:

1. A method for selectively delivering molecules to the nucleus of endothelium of the large vessels, comprising
administering a conjugate of an agent binding selectively to endothelial protein C receptor (EPCR) and the molecule to be delivered to large vessel endothelial cells, wherein the molecules are delivered to the nucleus of the large vessel endothelial cells.
2. The method of claim 1 wherein the conjugate is formed between the molecule to be delivered and an antibody to EPCR.
3. The method of claim 1 wherein the conjugate is formed between the molecule to be delivered and activated protein C.
4. The method of claim 1 wherein the conjugate comprises a chimeric antibody binding to the molecule to be delivered and to EPCR.
5. The method of claim 1 wherein the molecule to be delivered is a nucleic acid molecule and the nucleic acid molecule is a gene or cDNA under the control of a promoter expressed in the nucleus of an endothelial cell.
6. The method of claim 1 wherein the molecule to be delivered is a nucleic acid molecule and the nucleic acid molecule is selected from the group consisting of triplex forming oligonucleotides, ribozymes, guide sequences for ribozymes, and antisense.
7. The method of claim 1 wherein the molecule to be delivered is selected from the group consisting of drugs and diagnostic agents.
8. The method of claim 1 wherein the molecule to be delivered is a protein.
9. The method of claim 8 wherein the protein is a transcription factor.
10. The method of claim 1 wherein the molecule to be delivered is coupled to the agent which binds to EPCR by molecules selected from the group consisting of streptavidin and biotin, and molecules having multiple positive charges.
11. The method of claim 1 wherein the conjugate is administered to large vessel endothelial cells in culture or isolated from an individual.

12. The method of claim 1 wherein the conjugate is administered to an individual in need of treatment or diagnosis.
13. A conjugate of an agent binding selectively to endothelial protein C receptor (EPCR) selected from the group consisting of protein C, activated protein C, antibodies reactive with EPCR and fragments thereof binding to EPCR, and a molecule to be delivered to a large vessel endothelial cell, wherein the molecule is not a diagnostic label.
14. The conjugate of claim 13 wherein the conjugate is formed with an antibody to EPCR, or a fragment or recombinant molecule based thereon, binding to EPCR.
15. The conjugate of claim 13 wherein the conjugate is formed between the agent to be delivered and activated protein C.
16. The conjugate of claim 13 wherein the molecule to be delivered is a nucleic acid molecule.
17. The conjugate of claim 16 wherein the nucleic acid molecule is a gene or cDNA under the control of a promoter expressed in the nucleus of an endothelial cell.
18. The conjugate of claim 16 wherein the nucleic acid molecule is selected from the group consisting of triplex forming oligonucleotides, ribozymes, guide sequences for ribozymes, and antisense.
19. The conjugate of claim 13 wherein the molecule to be delivered is a drug.
20. The conjugate of claim 13 wherein the molecule to be delivered is a protein.
21. The conjugate of claim 20 wherein the protein is a transcription factor.
22. The conjugate of claim 20 comprising a coupling means which binds the molecule to be delivered to the agent which binds EPCR.
23. The conjugate of claim 22 wherein the coupling means is a positively charged polymer or molecule.

24. The conjugate of claim 22 wherein the coupling means is streptavidin-biotin.
25. The conjugate of claim 13 comprising a chimeric antibody which binds to EPCR and to the molecule to be delivered.

1/2




FIG. 1





FIG. 2

2/2

*FIG. 3*

INTERNATIONAL SEARCH REPORT

Inte: onal Application No

PCT/US 99/19480

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K45/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 98 55142 A (JAKUBOWSKI JOSEPH ANTHONY ; LILLY CO ELI (US); GRINNELL BRIAN WILLI) 10 December 1998 (1998-12-10) page 3, line 22 -page 5, line 33 page 7, line 21-25; claims 1-21 ---	1, 3, 7, 13, 15, 19
X	EP 0 687 687 A (IMMUNO AG) 20 December 1995 (1995-12-20) page 4, line 2-52 ---	13, 15, 20
X	WO 90 08556 A (BAXTER INT) 9 August 1990 (1990-08-09) page 5, line 30 -page 6, line 8 ---	13, 15, 20
X	WO 89 02747 A (AMERICAN NAT RED CROSS) 6 April 1989 (1989-04-06) page 5, line 11-17 ---	13, 15, 20
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"B" document member of the same patent family

Date of the actual completion of the international search

1 February 2000

Date of mailing of the international search report

09/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Engl, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/19480

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 318 201 A (SCRIPPS CLINIC RES) 31 May 1989 (1989-05-31) page 6, line 54; claims 1,6 ---	1, 3, 13, 15, 19, 20
P, A	WO 99 00673 A (OKLAHOMA MED RES FOUND) 7 January 1999 (1999-01-07) page 16, line 18 -page 18, line 6 ---	2, 14
A	WO 96 05303 A (OKLAHOMA MED RES FOUND) 22 February 1996 (1996-02-22) page 20, line 31 -page 23, line 11 page 27, line 13 -page 35, line 23 ---	1-12
A	US 5 009 889 A (TAYLOR JR FLETCHER B ET AL) 23 April 1991 (1991-04-23) the whole document ---	1-12
A	WO 98 20041 A (OKLAHOMA MED RES FOUND) 14 May 1998 (1998-05-14) page 7, line 4-21 -----	1-25

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/19480

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9855142	A	10-12-1998	AU 7710098 A		21-12-1998
			EP 0882453 A		09-12-1998
EP 0687687	A	20-12-1995	DE 4418635 A		30-11-1995
			CA 2150327 A		28-11-1995
			JP 8040929 A		13-02-1996
			US 5804181 A		08-09-1998
WO 9008556	A	09-08-1990	US 5093117 A		03-03-1992
			CA 1339990 A		11-08-1998
			DE 69019072 D		08-06-1995
			DE 69019072 T		30-11-1995
			DK 406398 T		17-07-1995
			EP 0406398 A		09-01-1991
			ES 2074563 T		16-09-1995
			JP 3503536 T		08-08-1991
WO 8902747	A	06-04-1989	NONE		
EP 0318201	A	31-05-1989	US 5084274 A		28-01-1992
			AT 135234 T		15-03-1996
			CA 1330036 A		07-06-1994
			DE 3855096 D		18-04-1996
			DE 3855096 T		25-07-1996
			DK 640088 A		18-05-1989
			ES 2086301 T		01-07-1996
			FI 885331 A		18-05-1989
			GR 3020036 T		31-08-1996
			JP 1238536 A		22-09-1989
			JP 2766986 B		18-06-1998
			NO 301747 B		08-12-1997
			US 5350578 A		27-09-1994
WO 9900673	A	07-01-1999	US 5804392 A		08-09-1998
			AU 8269498 A		19-01-1999
WO 9605303	A	22-02-1996	US 5695993 A		09-12-1997
			AU 707349 B		08-07-1999
			AU 3272395 A		07-03-1996
			CA 2199821 A		22-02-1996
			EP 0777731 A		11-06-1997
			US 5852171 A		22-12-1998
US 5009889	A	23-04-1991	NONE		
WO 9820041	A	14-05-1998	AU 5431798 A		29-05-1998
			EP 0937104 A		25-08-1999